(PR-inside.com) Ardea Biosciences, Inc. (Ardea) is a biotechnology company. It focuses on the development of small molecules as novel therapeutics for the treatment of gout and cancer. The company's product portfolio includes three pipeline products, namely, Lesinurad, RDEA 3170 and Bay 86-9766. Lesinurad and RDEA 3170 are currently in Phase-III and Phase-II clinical trials respectively, being developed as a treatment for gout. Bay 86-966 is a Phase-II clinical candidate being developed as a treatment for cancer in a global licensing agreement with Bayer. The company operates as a subsidiary of AstraZeneca PLC. Ardea is headquartered in San Diego, California, the US. Ardea ..
